Zentalis Pharmaceuticals Inc. - notizie pubblicate 214 - letture 3.643
ZENTALIS PHARMACEUTICALS INC.
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
San diego, july 01, 2024 (globe newswire) -- zentalis® pharmaceuticals, inc. (nasdaq: zntl), a clinical-stage biopharmaceutical company discovering and developing clinically diffe ...
ZENTALIS PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ZENTALIS PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ZENTALIS PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ZENTALIS PHARMACEUTICALS INC.
Submission of Matters to a Vote of Security Holders Form 8 K
Item 1 - election of two class i directors to serve until the 2027 annual meeting of stockholders, and until their respective successors shall have been duly elected and qualified, ...
ZENTALIS PHARMACEUTICALS INC.
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
Fda has placed a partial clinical hold on zn-c3-001, denali and teton monotherapy studies of azenosertib monotherapy data to be presented in the second half of 2024 conference call ...
ZENTALIS PHARMACEUTICALS INC.
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
New york & san diego, june 03, 2024 (globe newswire) -- zentalis® pharmaceuticals, inc. (nasdaq: zntl), a clinical-stage biopharmaceutical company discovering and developing c ...
ZENTALIS PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ZENTALIS PHARMACEUTICALS INC.
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
New york and san diego, may 30, 2024 (globe newswire) -- zentalis® pharmaceuticals, inc. (nasdaq: zntl), a clinical-stage biopharmaceutical company discovering and developing clin ...
ZENTALIS PHARMACEUTICALS INC.
Additional Proxy Soliciting Materials - Form DEFA14A
Document united states securities and exchange commission washington, dc 20549 schedule 14a schedule 14a information proxy statement pursuant to section 14(a) of the securities exc ...
ZENTALIS PHARMACEUTICALS INC.
Initial Statement of Beneficial Ownership - Form 3
Ownership submission form 3 united states securities and exchange commission washington, d.c. 20549initial statement of beneficial ownership of securities filed pursuant to section ...
ZENTALIS PHARMACEUTICALS INC.
Management Change/Compensation - Form 8-K
Item 5.02 departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers. on and effective may 24 ...
ZENTALIS PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ZENTALIS PHARMACEUTICALS INC.
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
New york and san diego, may 29, 2024 (globe newswire) -- zentalis® pharmaceuticals, inc. (nasdaq: zntl), a clinical-stage biopharmaceutical company discovering and developing clin ...
ZENTALIS PHARMACEUTICALS INC.
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer zentalis pharmaceuticals inc. publishe ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti